Drugs / Vonsetamig
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06975787 | Dec 2025 → Sep 2029 expected | lupus nephritis | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05092347 | Aug 2022 → Nov 2027 expected | chronic kidney disease | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04083534 | Sep 2019 → May 2025 | plasma cell myeloma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vonsetamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975787 ↗ |
| Known as | REGN5459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04083534 ↗ |
| Modality | Monoclonal antibody | “Anti-BCMA x Anti-CD3 Bispecific Antibody” NCT04083534 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT04083534 ↗ |